Scientists launch largest-ever natural history study for rare bone disease hypophosphatasia
NCT ID NCT02237625
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 200 children and adults with hypophosphatasia (HPP), a rare genetic disorder that weakens bones and teeth. Researchers will collect medical history, track disease progression, and assess quality of life over time. The goal is to better understand how HPP affects the body and what long-term complications may arise. No experimental treatments are given; this is purely an observation study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide crucial insights into how hypophosphatasia progresses, helping doctors improve care and develop better treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any new drug or therapy, so there is no direct benefit to participants. Results may take years to influence clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- Genetic deep dive uncovers hidden clues in rare bone disease
- Could your body fight back against this rare disease drug?
- New study tracks rare bone disease to unlock clues for better diagnosis
- Withdrawn study aimed to counteract antibodies blocking hypophosphatasia drug
- New study aims to cut diagnostic delays for rare bone disease